- Focus of specialty care on niche therapeutic areas and of primary
care on the gastrointestinal segment
- Sales growth acceleration with a 2020 outlook for organic sales of
€1.8bn to €2bn and a core operating margin1
of above 26%
Company Website:
http://www.ipsen.com
PARIS -- (Business Wire)
Regulatory News:
Ipsen (Euronext: IPN - ADR: IPSEY) will host today its Investor Day. The
Group’s management will provide a comprehensive review of its 2020
strategy.
Marc de Garidel, Chairman and Chief Executive Officer of Ipsen,
said: “We are sharing today an update on our 2020 targets. The Group
strategy presented to the financial markets in June 2011, calling for an
increased focus of Research and Development (R&D) and commercial
efforts, and geographical expansion in emerging markets and the United
States, generated solid growth of sales and profits over 2010-2015. We
are now entering the second phase of this strategic plan, characterized
by an acceleration of sales growth, with a 2020 outlook for organic
sales of €1.8bn to €2bn and a core operating margin of above 26%.”
Key strategic topics presented today include:
In specialty care:
-
A focus on three niche therapeutic areas where Ipsen has the potential
to become a leader: neuroendocrine tumors, spasticity, and the
aesthetic indication of Dysport® through our partnership
with Galderma;
-
The reinforcement of the Group’s presence in its historical
therapeutic areas: urology-oncology and adult endocrinology;
-
The exploration of adjacent therapeutic areas, in gastrointestinal
(GI) and orphan cancers.
In order to bring new specialty care products to the market in the
Group’s targeted therapeutic areas, R&D continues to focus on two
differentiated and innovative technological platforms, peptides and
toxins. In line with the strategy of exploring adjacent segments, R&D
will also deploy resources for the development of molecules for the
treatment of gastrointestinal and orphan cancers. Moreover, R&D will
continue its efforts to enter partnerships and make acquisitions to
complement internal pipeline.
In primary care:
-
Optimization of the GI portfolio;
-
Diversification on adjacent GI pathologies;
-
Reinforcement of geographical coverage.
1 In percentage of sales
The Group is also building an OTx1 commercial model to
benefit from its strong brand recognition and to maximize its commercial
reach.
Christel Bories, Deputy Chief Executive Officer of Ipsen, stated: “Our
industry is going through a deep strategic mutation and Ipsen continue
its transformation so as to be prepared for tomorrow’s challenges. We
are consistently improving our efficiency across all company
departments, with the goal of delivering profitable growth. We are
reiterating our focus on high-growth specialty care areas where Ipsen
has reference products and a leading position, while opening to adjacent
and synergistic segments. In primary care, we strive to return to
sustainable growth by drawing on our assets and on the Group’s strong
heritage in this field. We are convinced that this second strategic step
will allow us to become among the best performing companies in our
industry.”
2020 outlook includes:
-
Organic sales ranging between €1.8bn and €2bn, including pipeline
molecules;
-
Core Operating Margin2 above 26%, driven by the
profitability of the US platform in 2016 and transformation
initiatives led by the Group, notably in the commercial area.
Moreover, the Group continues its business development efforts,
simultaneously targeting molecules under development and commercialized
products in the Group’s targeted therapeutic areas, in the US, Europe,
and the emerging markets. The Group is also considering external growth
to reinforce its primary care business in Europe and emerging markets.
In line with the strategy of exploring adjacent therapeutic areas, the
Group will also look for opportunities in gastrointestinal and orphan
cancers. Potential business development deals will complement the €1.8bn
to €2.0bn 2020 organic sales target.
Press conference (in French)
Ipsen will host a press conference on Thursday 2 July 2015 at 9.00 a.m.
(Paris time, GMT + 1) at the ALMA-MARCEAU Conference Center, 12 avenue
Marceau – 75008 Paris (France).
Meeting, webcast and Conference Call (in English) for the financial
community
Ipsen will host an analyst meeting on Thursday 2 July 2015 at 2:00 p.m.
(Paris time, GMT+1) at the ALMA-MARCEAU Conference Center 12 avenue
Marceau – 75008 Paris (France). A web conference (audio and video
webcast) and conference call will take place simultaneously.
Participants in the conference call should dial in approximately 5 to 10
minutes prior to its start. No reservation is required to participate.
The conference ID is 953491. Phone numbers to call in order to connect
to the conference are: from France and continental Europe +33 (0) 1 70
99 32 09, from UK +44 (0) 20 71 31 27 11 and from the United States +1
646 461 1757. No access code is required. A recording will be available
shortly after the call. Phone numbers to access the replay of the
conference are: from France and continental Europe +33 (0) 1 70 99 35
29, from UK +44 (0) 20 70 31 40 64 and from the United States +1 954 334
0342 and access code is 953491. This replay will be available for one
week following the meeting.
1 |
|
|
OTx: Dual channel approach (Rx/OTC)
|
2 | | |
In percentage of sales
|
About Ipsen
Ipsen is a global specialty-driven biotechnological group with total
sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in
more than 115 countries, with a direct commercial presence in 30
countries. Ipsen’s ambition is to become a leader in specialty
healthcare solutions for targeted debilitating diseases. Its development
strategy is supported by 3 franchises: neurology, endocrinology and
urology-oncology. Ipsen’s commitment to oncology is exemplified through
its growing portfolio of key therapies improving the care of patients
suffering from prostate cancer, bladder cancer and neuro-endocrine
tumors. Ipsen also has a significant presence in primary care. Moreover,
the Group has an active policy of partnerships. Ipsen's R&D is focused
on its innovative and differentiated technological platforms, peptides
and toxins, located in the heart of the leading biotechnological and
life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US).
In 2014, R&D expenditure totaled close to €187 million, representing
about 15% of Group sales. The Group has more than 4,500 employees
worldwide. Ipsen’s shares are traded on segment A of Euronext Paris
(stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service
de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index.
Ipsen has implemented a Sponsored Level I American Depositary Receipt
(ADR) program, which trade on the over-the-counter market in the United
States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.Ipsen
Forward Looking Statement
The forward-looking statements, objectives and targets contained herein
are based on the Group’s management strategy, current views and
assumptions. Such statements involve known and unknown risks and
uncertainties that may cause actual results, performance or events to
differ materially from those anticipated herein. All of the above risks
could affect the Group’s future ability to achieve its financial
targets, which were set assuming reasonable macroeconomic conditions
based on the information available today. Use of the words "believes,"
"anticipates" and "expects" and similar expressions are intended to
identify forward-looking statements, including the Group’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document were
prepared without taking into account external growth assumptions and
potential future acquisitions, which may alter these parameters. These
objectives are based on data and assumptions regarded as reasonable by
the Group. These targets depend on conditions or facts likely to happen
in the future, and not exclusively on historical data. Actual results
may depart significantly from these targets given the occurrence of
certain risks and uncertainties, notably the fact that a promising
product in early development phase or clinical trial may end up never
being launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. The Group must face or might face
competition from generic products that might translate into a loss of
market share. Furthermore, the Research and Development process involves
several stages each of which involves the substantial risk that the
Group may fail to achieve its objectives and be forced to abandon its
efforts with regards to a product in which it has invested significant
sums. Therefore, the Group cannot be certain that favourable results
obtained during pre-clinical trials will be confirmed subsequently
during clinical trials, or that the results of clinical trials will be
sufficient to demonstrate the safe and effective nature of the product
concerned. There can be no guarantees a product will receive the
necessary regulatory approvals or that the product will prove to be
commercially successful. If underlying assumptions prove inaccurate or
risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks and
uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation; global
trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approval; the
Group's ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the
effectiveness of the Group’s patents and other protections for
innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions. The Group also depends on third
parties to develop and market some of its products which could
potentially generate substantial royalties; these partners could behave
in such ways which could cause damage to the Group’s activities and
financial results. The Group cannot be certain that its partners will
fulfil their obligations. It might be unable to obtain any benefit from
those agreements. A default by any of the Group’s partners could
generate lower revenues than expected. Such situations could have a
negative impact on the Group’s business, financial position or
performance. The Group expressly disclaims any obligation or undertaking
to update or revise any forward looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such statements
are based, unless so required by applicable law. The Group’s business is
subject to the risk factors outlined in its registration documents filed
with the French Autorité des Marchés Financiers.
The risks and uncertainties set out are not exhaustive and the reader is
advised to refer to the Group’s 2014 Registration Document available on
its website (www.ipsen.com).
View source version on businesswire.com: http://www.businesswire.com/news/home/20150701006598/en/
Contacts:
For further information:
Ipsen
Media
Didier
Véron
Senior Vice-President, Public Affairs
and
Communication
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33
50 58
E-mail:
didier.veron@ipsen.com
or
Brigitte
Le Guennec
Corporate External Communication Manager
Tel.:
+33 (0)1 58 33 51 17
Fax: +33 (0)1 58 33 50 58
E-mail : brigitte.le.guennec@ipsen.com
or
Financial
Community
Stéphane Durant des Aulnois
Vice-President,
Investor Relations
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58
33 50 63
E-mail: stephane.durant.des.aulnois@ipsen.com
Source: Ipsen
© 2024 Canjex Publishing Ltd. All rights reserved.